Eli Lilly and Company (NYSE:LLY) major shareholder Lilly Endowment Inc sold 215,000 shares of Eli Lilly and Company stock in a transaction on Tuesday, June 20th. The stock was sold at an average price of $83.05, for a total value of $17,855,750.00. Following the transaction, the insider now directly owns 124,475,804 shares of the company’s stock, valued at $10,337,715,522.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Lilly Endowment Inc also recently made the following trade(s):
- On Thursday, June 22nd, Lilly Endowment Inc sold 210,000 shares of Eli Lilly and Company stock. The stock was sold at an average price of $84.43, for a total value of $17,730,300.00.
- On Thursday, March 30th, Lilly Endowment Inc sold 210,000 shares of Eli Lilly and Company stock. The stock was sold at an average price of $84.67, for a total value of $17,780,700.00.
Shares of Eli Lilly and Company (NYSE:LLY) opened at 83.89 on Monday. The stock has a market cap of $88.61 billion, a P/E ratio of 40.57 and a beta of 0.36. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $86.72. The stock has a 50 day moving average price of $80.12 and a 200-day moving average price of $79.31.
Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, April 25th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.96 by $0.02. The company had revenue of $5.23 billion during the quarter, compared to analyst estimates of $5.22 billion. Eli Lilly and Company had a return on equity of 26.64% and a net margin of 10.13%. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.83 earnings per share. On average, analysts forecast that Eli Lilly and Company will post $4.12 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be issued a $0.52 dividend. The ex-dividend date is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.48%. Eli Lilly and Company’s payout ratio is currently 100.48%.
TRADEMARK VIOLATION WARNING: “Insider Selling: Eli Lilly and Company (LLY) Major Shareholder Sells $17,855,750.00 in Stock” was originally reported by sleekmoney and is the sole property of of sleekmoney. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://sleekmoney.com/insider-selling-eli-lilly-and-company-lly-major-shareholder-sells-17855750-00-in-stock/1940033.html.
LLY has been the subject of a number of analyst reports. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $92.00 price target on shares of Eli Lilly and Company in a report on Tuesday, May 16th. BMO Capital Markets set a $71.00 price target on Eli Lilly and Company and gave the stock a “sell” rating in a report on Tuesday, April 25th. Zacks Investment Research cut Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Tuesday, April 18th. Credit Suisse Group reissued an “outperform” rating and issued a $87.00 price target on shares of Eli Lilly and Company in a report on Wednesday, April 19th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $97.00 price target (up from $95.00) on shares of Eli Lilly and Company in a report on Saturday, March 11th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Eli Lilly and Company presently has a consensus rating of “Hold” and an average target price of $87.65.
Several hedge funds have recently added to or reduced their stakes in LLY. Nisa Investment Advisors LLC raised its stake in Eli Lilly and Company by 3.1% in the first quarter. Nisa Investment Advisors LLC now owns 324,377 shares of the company’s stock worth $27,280,000 after buying an additional 9,680 shares during the last quarter. Franklin Street Advisors Inc. NC acquired a new stake in Eli Lilly and Company during the first quarter worth about $320,000. Washington Trust Bank raised its stake in Eli Lilly and Company by 92.8% in the first quarter. Washington Trust Bank now owns 10,369 shares of the company’s stock worth $872,000 after buying an additional 4,990 shares during the last quarter. Independent Advisor Alliance acquired a new stake in Eli Lilly and Company during the fourth quarter worth about $1,547,000. Finally, Pinnacle Associates Ltd. raised its stake in Eli Lilly and Company by 16.6% in the fourth quarter. Pinnacle Associates Ltd. now owns 48,177 shares of the company’s stock worth $3,543,000 after buying an additional 6,873 shares during the last quarter. Institutional investors own 75.49% of the company’s stock.
About Eli Lilly and Company
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/insider-selling-eli-lilly-and-company-lly-major-shareholder-sells-17855750-00-in-stock/1940033.html
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.